United States· US:82260-496_2f9f1dcc-6988-edb0-e063-6394a90ac484
Timolol Maleate
A timolol product containing timolol maleate, registered in United States by Bausch & Lomb Americas Inc.. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Timolol is registered in 14 of 19 countries.
Countries holding a registration under ATC S01ED01 (timolol), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Timolol · ATC S01ED01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of timolol costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Timolol · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- IT Italy$2.87
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- TIMOLOL MALEATE
- Manufacturer
- Bausch & Lomb Americas Inc.
- Country
- United States (US)
- ATC code
- S01ED01
- ATC class
- Timolol
- Defined daily dose
- 0.2 g, AS
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1182260496056 POUCH in 1 CARTON (82260-496-05) / 10 CONTAINER in 1 POUCH / .3 mL in 1 CONTAINER
- ndc1182260-496-05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
144 interactions on record for timolol.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Timolol · interactions on record
144 records
- 28 severe
- 114 moderate
- 2 minor
Most severe, free to view
- EpinephrineB02BC09severe
- EpinephrineC01CA24severe
- OrciprenalinC01CA29severe
- TheophyllinC01EB28severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under S01ED01
Timolol, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d77667fc-af98-4557-b6a0-9c1974fcb87c GET /v1/drugs/d77667fc-af98-4557-b6a0-9c1974fcb87c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "OPHTHALMIC",
"source": "ndc",
"strength": "6.8",
"substance": "TIMOLOL MALEATE",
"productndc": "82260-496",
"dosage_form": "SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "NDA019463",
"marketing_category": "NDA AUTHORIZED GENERIC"
}See everything about timolol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.